Advances in Hematology / 2012 / Article / Tab 1

Review Article

Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited

Table 1

Incidence of SPMs with lenalidomide (Len) maintenance versus placebo in prospective, randomized phase 3 trials.

TrialReference F/ua (mo)Treatment prior to randomizationRandomized armsInvasive SPMs (no.)Solid cancers (no.)Heme cancers (no.)Nonmelanoma skin cancers (no.)Cumulative incidence of invasive cancers (%)Incidence
(per 100 patient-years)

IFM 2005-002 [54] 614 45Induction then SCTLen23101357.53.1
Placebo94532.91.2

CALGB 100104 [55] 460 34Induction then SCTLen1810847.8N/A
Placebo65132.6N/A

MPR-R1257171.4
MM-015[56, 57]45930MPR or MPMPR945472.1
MP431530.7

a Median followup from the time from randomization.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.